Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease

scientific article published on 25 July 2015

Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/BRAIN/AWV219
P698PubMed publication ID26210536
P5875ResearchGate publication ID280446363

P50authorShitij KapurQ20713543
Eugenii A. RabinerQ56097267
Paola PicciniQ64856193
Marios PolitisQ64856266
Flavia NiccoliniQ90879542
Graham E SearleQ122914788
Roger N. GunnQ41909429
Sridhar NatesanQ47504364
Nils MuhlertQ47504365
Tiago Reis MarquesQ47504367
P2093author name stringThomas Foltynie
Andri C Tziortzi
P2860cites workDistinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatumQ23909635
Statistical parametric maps in functional imaging: A general linear approachQ27864122
Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10AQ28574633
Immunohistochemical localization of PDE10A in the rat brainQ28581263
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brainQ29614725
Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia.Q30493549
A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volumeQ30970553
Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species.Q48463634
Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.Q48546793
Fluid and white matter suppression with the MP2RAGE sequence.Q48777579
Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures.Q48810366
Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A.Q48947947
Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.Q49080012
Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatumQ49155446
Nonlinear spatial normalization using basis functionsQ53178416
Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascadeQ33703262
Region of interest template for the human basal ganglia: comparing EPI and standardized space approachesQ36476491
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's diseaseQ36901896
History of falls in Parkinson disease is associated with reduced cholinergic activityQ37459699
Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PDQ37536347
Pathology of Parkinson's disease. Changes other than the nigrostriatal pathwayQ37543216
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patientsQ37602233
Brain activity during complex imagined gait tasks in Parkinson diseaseQ37695009
Integrating neurotransmission in striatal medium spiny neurons.Q37986667
Deep brain stimulation for gait and postural symptoms in Parkinson's diseaseQ38153335
In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654.Q39180707
Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.Q39205398
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.Q39801798
A high resolution and high contrast MRI for differentiation of subcortical structures for DBS targeting: the Fast Gray Matter Acquisition T1 Inversion Recovery (FGATIR).Q39988148
Cell communication, calcium ion, and cyclic adenosine monophosphateQ41511554
PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.Q42487128
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's diseaseQ42543320
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET studyQ42994792
[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progressionQ43820139
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesiaQ44383212
PET imaging shows loss of striatal PDE10A in patients with Huntington diseaseQ45296605
Modification of Parkinsonism--chronic treatment with L-dopaQ45300970
The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington diseaseQ45302323
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.Q46418668
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiationQ46904268
Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brainQ46976056
The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's diseaseQ48119124
Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson's diseaseQ48128786
Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomyQ48140763
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?Q48433626
P433issuePt 10
P407language of work or nameEnglishQ1860
P304page(s)3003-3015
P577publication date2015-07-25
P1433published inBrainQ897386
P1476titleLoss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease
P478volume138

Reverse relations

cites work (P2860)
Q64968192A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys
Q90198060Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
Q52099206Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
Q48906405Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates.
Q37560665Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain
Q92217551Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme
Q28390557Comparison of [(11)C]TZ1964B and [(18)F]MNI659 for PET imaging brain PDE10A in nonhuman primates
Q47242194Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases
Q48093702Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry
Q45305673Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Q36802579De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions
Q64785657Imaging Markers of Progression in Parkinson's Disease
Q31119042Imaging in Parkinson's disease.
Q91621387Imaging phosphodiesterase-10a availability in cocaine use disorder with [11 C]IMA107 and PET
Q50200295In vivo characterization of two 18F-labeled PDE10A PET radioligands in nonhuman primate brains.
Q51640625Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005.
Q31158920Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
Q85888036Neurodegenerative disease: Changes in brain phosphodiesterase 10A levels in neurodegenerative basal ganglia disorders
Q52317290New Imaging Markers for Movement Disorders.
Q26746978Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012
Q57456370PET Imaging in Movement Disorders
Q42369736PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease
Q46354756Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
Q38686069Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease
Q39029199Phosphodiesterase 10 inhibitors in clinical development for CNS disorders
Q26753116Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications
Q42504663Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia.
Q89972944Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease
Q33635522Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study
Q48272772TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia
Q37740539The Phosphodiesterase 10A Inhibitor PF-2545920 Enhances Hippocampal Excitability and Seizure Activity Involving the Upregulation of GluA1 and NR2A in Post-synaptic Densities.
Q92461195Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond

Search more.